Arjun V. Balar, MD | Authors


Good News: ODAC’s Approvals Are Based on Subjective Decisions

June 16, 2021

Arjun V. Balar, MD, co-physician editor in chief of Targeted Therapies in Oncology, discusses the proceedings of the 3-day Oncologic Drug Advisory Committee meeting on accelerated approvals for PD-1/PD-L1 antibodies in solid tumor indications that failed to show confirmatory benefit.

Overcoming Widespread Effects of COVID-19 Calls for Resilience, Perseverance

November 22, 2020

The economic impact of the pandemic, which is still taking shape, will likely lead to many patients being uninsured, resulting in less access to medical care and ultimately culminating in an uptick in cancer-related mortality in the years ahead.